D. Western Therapeutics Institute, Inc.
Stock Price Chart
2026/10/08 19:22 UpdatedPrice Trend
2026/10/08 19:22 UpdatedPrice & Trading Details
2026/10/08 19:22 UpdatedPRICE
TRADING
Shareholder Composition
Updated 2026/10/01Financial Performance
2026/10/04 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥448M | ¥428M | ¥472M | ¥388M |
| Gross Profit | ¥421M | ¥392M | ¥425M | ¥349M |
| Operating Income | -¥306M | -¥799M | -¥1,210M | -¥620M |
| Pretax Income | -¥437M | -¥824M | -¥1,283M | -¥622M |
| Net Income | -¥430M | -¥812M | -¥1,290M | -¥632M |
| EPS | -¥14.50 | -¥25.56 | -¥36.74 | -¥13.19 |
| Operating Margin | -68.27% | -186.42% | -256.50% | -159.92% |
| Balance Sheet | ||||
| Total Assets | ¥2,956M | ¥2,373M | ¥1,669M | ¥2,169M |
| Total Equity | ¥1,857M | ¥1,280M | ¥734M | ¥1,435M |
| Total Liabilities | ¥1,099M | ¥1,094M | ¥936M | ¥734M |
| Cash | ¥2,335M | ¥1,867M | ¥1,126M | ¥1,710M |
| Interest-bearing Debt | ¥968M | ¥885M | ¥798M | ¥605M |
| Equity Ratio | 62.83% | 53.92% | 43.96% | 66.17% |
| D/E Ratio | 0.52 | 0.69 | 1.09 | 0.42 |
| Cash Flow | ||||
| Operating CF | -¥355M | -¥587M | -¥1,299M | -¥494M |
| Investing CF | -¥140M | -¥15M | -¥10M | -¥2M |
| Financing CF | ¥867M | ¥134M | ¥568M | ¥1,080M |
| Free CF | -¥365M | -¥602M | -¥1,309M | -¥497M |
| Efficiency | ||||
| ROE | -23.13% | -63.48% | -175.82% | -44.03% |
| ROA | -14.53% | -34.23% | -77.29% | -29.14% |
Latest IR Information
-
Notice of Completion of Payment for Issuance of the 14th Stock Acquisition Rights (with Exercise Price Adjustment Clause) by Third-Party Allotment and Issuance of the 2nd Unsecured Corporate Bonds
Announced issuance of stock acquisition rights and completion of issuance/payment for unsecured corporate bonds. Total issuance amounts are 14,430,000 yen for the stock acquisition rights and 500,000,000 yen for the bonds. Allottees include Growth Capital and others; details are provided...
Read more -
Regarding U.S. Distribution Partnership and Launch Timing for Bondlido
Regarding Bondlido's U.S. distribution partnership and launch timing: the sales license agreement is expected to be signed in October, and the launch is expected in Q4 2026. Renegotiation of contract terms is taking additional time; revenue impact is uncertain but...
Read more -
Notice of Completion of Acquisition and Cancellation of the 13th Stock Acquisition Rights and Monthly Exercise Status
All 13th-series stock acquisition rights were acquired and canceled. No impact on current period results. For the monthly exercise status, of 40,000 shares granted, 81 shares were exercised, and unexercised rights decreased to 7,938.
Read more -
Notice Regarding Early Repayment of Borrowings
Repayment of borrowings ahead of schedule for two facilities. Repayment date set for September 30, 2026, using fixed deposits at Mizuho Bank. Impact expected to be minor on the consolidated results for the December 2026 period.
Read more -
Domestic development plan for the glaucoma treatment agent H-1337 announced
Decision on domestically focused development plan for H-1337. Initiate Japanese clinical trials in a phased manner, aiming to finalize small-scale dose confirmation in 2027 and commence domestic Phase III trials in 2029. Late-stage II trials in the United States continue....
Read more
Latest News (5 items)
Company Information
About
D. Western Therapeutics Institute, Inc., a biotechnology company, focuses on discovery and development of various drugs. It offers GLANATEC and GLA-ALPHA, an ophthalmic solution for the treatment of glaucoma/ocular hypertension; H-1337, a multi-kinase inhibitor that has started Phase IIb clinical trials for the treatment of glaucoma/ocular hypertension; DW-1001, an ophthalmic drug; and DW-1002, an ophthalmic surgical adjuvant for cataract surgeries, and ILM, ALC, ERM, and PVR membrane staining. The company is also developing DW-5LBT, a lidocaine patch for neuropathic pain after shingles; and DWR-2206, a regenerative medicine cell-product for bullous keratopathy. D. Western Therapeutics Institute, Inc. was founded in 1999 and is headquartered in Nagoya, Japan.
